Pharming Group
PHAR
Company Profile
Business description
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Contact
Darwinweg 24
LeidenZH2333 CR
NLDT: +31 715247400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
404
Stocks News & Analysis
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,819.40 | 9.30 | -0.11% |
| CAC 40 | 7,953.96 | 17.99 | 0.23% |
| DAX 40 | 23,533.40 | 30.61 | -0.13% |
| Dow JONES (US) | 46,946.41 | 387.94 | 0.83% |
| FTSE 100 | 10,344.38 | 26.69 | 0.26% |
| HKSE | 25,868.54 | 34.52 | 0.13% |
| NASDAQ | 22,374.18 | 268.82 | 1.22% |
| Nikkei 225 | 53,700.39 | 50.76 | -0.09% |
| NZX 50 Index | 13,182.23 | 17.65 | 0.13% |
| S&P 500 | 6,699.38 | 67.19 | 1.01% |
| S&P/ASX 200 | 8,614.30 | 4.40 | -0.05% |
| SSE Composite Index | 4,049.91 | 34.88 | -0.85% |